ERBB2 and breast carcinoma: Since the development of resistance to HER2-targeted therapy is common amongst HER2-positive breast cancer patients, it has prompted investigation into use of a combinatorial therapeutic regimen that combines anti-HER2 mAb with chemotherapeutic agents.